CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- Acute Biphenotypic Leukemia
- Acute Lymphoblastic Leukemia
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- CD19 Positive
- Minimal Residual Disease
- Non Hodgkin Lymphoma
- Small Lymphocytic Lymphoma
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 1 years and 80 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To determine the safety and maximum tolerated dose of genetically modified, CD19-specific T cells administered into patients with CD19+ advanced lymphoid malignancies. SECONDARY OBJECTIVES: I. To screen for the development of host immune responses against the CD19-specific chi...
PRIMARY OBJECTIVES: I. To determine the safety and maximum tolerated dose of genetically modified, CD19-specific T cells administered into patients with CD19+ advanced lymphoid malignancies. SECONDARY OBJECTIVES: I. To screen for the development of host immune responses against the CD19-specific chimeric antigen receptor (CAR). II. To describe the homing ability of the infused T cells. III. To assess disease response. IV. To determine persistence of CAR+ T cells. OUTLINE: This is a dose escalation study of CD19 positive chimeric antigen receptor T-cells. LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of fludarabine phosphate intravenously (IV) over 1 hour and cyclophosphamide IV over 3 hours on days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the treating physician. Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0 and 1. After completion of study treatment, patients are followed up for at least 15 years.
Tracking Information
- NCT #
- NCT02529813
- Collaborators
- National Cancer Institute (NCI)
- Ziopharm Oncology
- Investigators
- Principal Investigator: Partow Kebriaei M.D. Anderson Cancer Center